1,692 research outputs found
Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis
The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these aller-
gens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the
searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we
selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials).
The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immu-
notherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to
the relevant food allergen significantly decreased with immunotherapy (mean difference
2
2·96 mm, 95 % CI
2
4·48,
2
1·45), while aller-
gen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6)
m
g/ml. Sensitivity analyses excluding studies at the highest risk
of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of
effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastro-
intestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of
systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immu-
notherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity
of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside
experimental conditions presently
Development and Characterization of Nonpeptidic Small Molecule Inhibitors of the XIAP/Caspase-3 Interaction
AbstractElevated expression of inhibitor of apoptosis protein (IAP) family members in various types of cancers is thought to provide a survival advantage to these cells. Thus, antiapoptotic functions of IAPs, and their potential as novel anticancer targets have attracted considerable interest. Among the IAPs, the X chromosome-linked inhibitor of apoptosis protein (XIAP) is regarded as the most potent suppressor of mammalian apoptosis through direct binding and inhibition of caspases. A high-throughput biochemical screen of a combinatorial chemical library led to the discovery of a novel nonpeptidic small molecule that has the ability to disrupt the XIAP/caspase-3 interaction. The activity of this nonpeptidic small molecule inhibitor of the XIAP/caspase-3 interaction has been characterized both in vitro and in cells. Molecules of this type can be used to conditionally inhibit the cellular function of XIAP and may provide insights into the development of therapeutic agents that act by modulating apoptotic pathways
Dss1 is a 26S proteasome ubiquitin receptor
The ubiquitin-proteasome system is the major pathway for protein degradation in eukaryotic cells. Proteins to be degraded are conjugated to ubiquitin chains that act as recognition signals for the 26S proteasome. The proteasome subunits Rpn10 and Rpn13 are known to bind ubiquitin, but genetic and biochemical data suggest the existence of at least one other substrate receptor. Here, we show that the phylogenetically conserved proteasome subunit Dss1 (Sem1) binds ubiquitin chains linked by K63 and K48. Atomic resolution data show that Dss1 is disordered and binds ubiquitin by binding sites characterized by acidic and hydrophobic residues. The complementary binding region in ubiquitin is composed of a hydrophobic patch formed by I13, I44, and L69 flanked by two basic regions. Mutations in the ubiquitin-binding site of Dss1 cause growth defects and accumulation of ubiquitylated proteins
- …